Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Share-based Compensation (2020 - 2025)

BioAtla (BCAB) has disclosed Share-based Compensation for 6 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 42.0% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $5.4 million, down 39.09%, while the annual FY2025 figure was $5.4 million, 39.09% down from the prior year.
  • Share-based Compensation hit $1.1 million in Q4 2025 for BioAtla, down from $1.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.3 million in Q2 2021 and bottomed at $1.1 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $3.4 million, with a median of $3.5 million recorded in 2022.
  • Year-over-year, Share-based Compensation grew 26.08% in 2021 and then tumbled 68.76% in 2022.
  • BioAtla's Share-based Compensation stood at $3.8 million in 2021, then decreased by 8.11% to $3.5 million in 2022, then decreased by 21.79% to $2.7 million in 2023, then dropped by 29.47% to $1.9 million in 2024, then crashed by 42.0% to $1.1 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $1.1 million, $1.3 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.